The global chronic Granulomatous disease (CGD) management market is expected to garner a market value of USD 1.31 Billion in 2023 and is expected to accumulate a market value of USD 2.11 Billion by registering a CAGR of 4.9% in the forecast period 2023 to 2033. Growth of the chronic Granulomatous disease (CGD) management market can be attributed to increasing research and development activities by key players for developing medications. the market for chronic Granulomatous disease (CGD) management registered a CAGR of 3.3% in the historical period 2018 to 2022.
The chronic granulomatous disease is a severe genetic condition that is passed down through the generations. People who suffer from this disease have weakened immune systems, making them subject to chronic inflammation and bacterial and fungal infections. The signs and symptoms of this condition appear in infancy or early childhood.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 1.31 Billion |
| Anticipated Forecast Value (2033) | USD 2.11 Billion |
| Projected Growth Rate (2023 to 2033) | 4.9% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Chronic Granulomatous disease (CGD) management reflected a value of 3.3% during the historical period, 2018 to 2022.
Chronic granulomatous disease or CGD is a kind of disorder under which white blood cells (phagocytes) are unable to kill certain types of bacteria and fungi. It is basically an inherited primary immunodeficiency disease caused by defects in the NADPH oxidase complex resulting in respiratory bursts in phagocytic leukocytes. The patients might develop skin infections, lymph node infections, pneumonia, lung infections, liver infections, gastrointestinal inflammation, or other infections. Thus, with the unique nature of CGD, the development of medications has increased rapidly. In the upcoming years, technological integration and research will boost the market for CGD management market.
Thus, the market for Chronic Granulomatous disease (CGD) management is expected to register a CAGR of 4.9% in the forecast period 2023 to 2033.
Research and development activities boosting the growth of the CGD market
The fact that 1 in 200000 or 250000 people suffer from CGD makes it a rare disease. In addition, the signs and symptoms of this illness differ from person to person. Frequent bacterial and fungal infections, swollen lymph nodes, recurrent diarrhoea, and abscesses involving the liver, lungs, spleen, bones, or skin are some of the most prevalent signs and symptoms.
The market is expected to rise due to factors such as the rising prevalence of rare illnesses, increased healthcare spending in developed economies, and increased research and development activities.
Changing lifestyles along with advancements in technology to innovate medication accelerating market growth
Factors such as the changes adopted in lifestyle and alterations in food habits is further expected to accelerate the overall growth of the chronic granulomatous disease treatment market within the forecast period. Additionally, the growing prevalence of rare diseases in some developing countries and increasing research and development activities boost the overall market’s demand.
Additionally, the advancement in technology and rising government funding for the healthcare sector are to further extend suitable opportunities for the growth of the chronic granulomatous disease treatment market in the near future.
Principal Consultant
Expensive nature of the treatment along with the lack of awareness hampering the market growth
The unavailability of effective treatments for different types of chronic granulomatous disease along with the high cost associated with treatment and diagnostic tests of chronic granulomatous disease is anticipated to most likely obstruct the growth of the chronic granulomatous disease treatment market in the coming years.
The lack of awareness about the disease in developing and underdeveloped economies can be one of the challenging factors within the forecast period. For example, Genetic testing might cost anything from USD 100 to USD 2,000. All these factors are hampering the growth of the CGD market.
Research and development activities create lucrative opportunities for market growth
The North American region is expected to hold the largest market share for the CGD market. This is due to a well-developed healthcare sector, the rising prevalence of rare diseases, the steadily growing occurrence of chronic granulomatous disease (CGD), and a relatively large number of research and development activities in the North American region.
According to a 2017 report published by the National Center for Biotechnology Information (NCBI), CGD affects 1 in 200,000 to 1 in 250,000 births in the United States. This, in turn, has created lucrative opportunities for innovating medication for treating the ailment. Furthermore, increased government support for the healthcare sector in the region is another factor driving the growth of the market. Thus, the North American region is expected to dominate the Chronic Granulomatous Disease by possessing a 45% market share in 2023.
Development of the healthcare sector shaping the landscape for the CGD market
The rising prevalence of rare diseases, as well as increased research and development activities, are driving market growth in this region. According to Eurostat, gross domestic expenditure (GERD) on research and development was EUR 303 billion in 2016.
In addition, increasing government funding for the healthcare sector and increasing research and development activities are changing the landscape for the CGD market. With the strong presence of key players in the region, Europe is expected to hold a 35% market share in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Detection of symptoms in early age advancing growth of X-linked CGD
Based on the Type, the market is segmented into X-Linked Chronic Granulomatous Disease and Autosomal Recessive Chronic Granulomatous Disease.
Patients with X-linked CGD often develop infections in their first ten years of life, and around 40% of them die before they reach the age of 35. Males are more likely than females to develop the chronic granulomatous disease. Approximately two-thirds of people in North American and European research had the X-linked recessive type of the disease. CGD is present at birth because it is a hereditary condition.
CGD symptoms normally appear throughout childhood or early adolescence, but they can sometimes be delayed until the early adolescent years. The earliest symptoms have been found to appear in adults in a few cases. The chronic granulomatous disease affects approximately four to five people in every Billion people globally.
Thus, the X-Linked Chronic Granulomatous Disease segment is expected to possess 52% market for the CGD market in 2023.
Trimethoprim exhibiting promising results for treating CBD
Based on the Treatment, the market is segmented into Infection Management, Trimethoprim, Sulfamethoxazole, Itraconazole, Interferon-gamma, Stem cell transplantation, and others. Trimethoprim is expected to hold the largest share of the CGD market in 2023.
Continuous antibiotic medication to help prevent infections, such as trimethoprim for bacterial infections and itraconazole for fungal infections, is used to treat chronic granulomatous illness. Antibiotics are usually required for infections. Corticosteroid medications can also help with granulomatous consequences. In some people with CGD, bone marrow transplants have been shown to be beneficial.
Thus, Trimethoprim is expected to possess a 40% market share for the CGD market in 2023.
Hospitals increasing accessibility for treatment of CBD management market
Based on the end-user, the market is segmented into Hospitals, Clinical laboratories, and Others. The hospital segment is expected to hold the largest market share in 2023.
This is due to the growing number of Chronic Granulomatous Disease patients increasing the treatments of Chronic Granulomatous Disease in hospitals. Hospitals are a significant part of the healthcare industry and a key source of revenue for the overall industry, which stimulates research and innovation.
As a result, a number of firms devote large resources to promoting their products and services among hospitals, both in terms of revenue and marketing tactics. Due to these factors, strategic decisions made in the hospital sector can have an impact on other sectors of the healthcare industry, providing them significant control over contract conditions with suppliers, service providers, and distributors.
These are the key factors that are expected to drive the growth of the hospital segment in the Chronic Granulomatous Disease Market during the forecast period. Thus, hospitals are expected to possess a 40% market share in the CBD management market.
Key players in the chronic Granulomatous disease (CGD) management market are Clinigen Group plc, Orchard Therapeutics plc, Horizon Therapeutics plc, ViroMed. Co. Ltd, Bellicum Pharmaceuticals, Inc, Pfizer Inc, Hoffmann-La Roche Ltd, Novartis AG, Lonza, GlaxoSmithKline plc, Eli Lilly and Company, Johnson & Johnson Services, Inc, Merck KGaA
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 1.31 Billion |
| Market Value in 2033 | USD 2.11 Billion |
| Growth Rate | CAGR of 4.9% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Type, Diagnosis, Treatment, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa (MEA) |
| Key Countries Profiled | The United States of America, Canada, Brazil, Argentina, Germany, The United Kingdom, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, Association of Southeast Asian Nations (ASEAN), GCC, South Africa |
| Key Companies Profiled | Clinigen Group plc; Orchard Therapeutics plc2032; Horizon Therapeutics plc; ViroMed. Co. Ltd; Bellicum Pharmaceuticals, Inc; Pfizer Inc; Hoffmann-La Roche Ltd; Novartis AG; Lonza; GlaxoSmithKline plc; Eli Lilly and Company; Johnson & Johnson Services, Inc; Merck KGaA |
| Customization | Available Upon Request |
The industry will reach a market value of USD 1.31 billion in 2023.
The market witnessed 3.3% historically.
North America is likely to generate 45% revenue in 2023.
Europe's market size is expected to hold a 35% share in 2023.
The market is expected to record a 4.9% CAGR until 2033.
1. Executive Summary | Chronic Granulomatous Disease (CGD) Management Market 2. Market Overview 3. Market Background 4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type 5.1. X-Linked Chronic Granulomatous Disease 5.2. Autosomal Recessive Chronic Granulomatous Disease 6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis 6.1. Neutrophil Function Tests 6.2. Genetic Testing 6.3. Prenatal Testing 6.4. Others 7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 7.1. Infection Management 7.2. Trimethoprim 7.3. Sulfamethoxazole 7.4. Itraconazole 7.5. Interferon-gamma 7.6. Stem Cell Transplantation 7.7. Others 8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-User 8.1. Hospitals 8.2. Clinical Laboratory 8.3. Homecare 8.4. Others 9. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. North America 9.2. Latin America 9.3. Europe 9.4. South Asia 9.5. East Asia 9.6. Oceania 9.7. Middle East & Africa (MEA) 10. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. South Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. East Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Oceania Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. MEA Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 17. Key Countries Analysis 18. Market Structure Analysis 19. Competition Analysis 19.1. Clinigen Group plc 19.2. Orchard Therapeutics plc 19.3. Horizon Therapeutics plc 19.4. ViroMed Co. Ltd 19.5. Bellicum Pharmaceuticals, Inc. 19.6. Pfizer Inc. 19.7. F. Hoffmann-La Roche Ltd 19.8. Novartis AG 19.9. Lonza 19.10. GlaxoSmithKline plc. 19.11. Eli Lilly and Company 19.12. Johnson & Johnson Services, Inc. 19.13. Merck KGaA 20. Assumptions & Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Chronic Granulomatous Disease (CGD) Management Market
